P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970580.01478.5b |
| _version_ | 1827332456826535936 |
|---|---|
| author | Michael Gundesen Fredrik Schjesvold Annette Vangsted Carsten Helleberg Einar Haukås Trine Silkjær Elena Todorescu Bo Amdi Jensen Tobias S. Slørdahl Jon Thor Asmussen Hareth Nahi Anders Waage Niels Abildgaard Thomas Lund |
| author_facet | Michael Gundesen Fredrik Schjesvold Annette Vangsted Carsten Helleberg Einar Haukås Trine Silkjær Elena Todorescu Bo Amdi Jensen Tobias S. Slørdahl Jon Thor Asmussen Hareth Nahi Anders Waage Niels Abildgaard Thomas Lund |
| author_sort | Michael Gundesen |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:00:13Z |
| format | Article |
| id | doaj.art-a108a6b70f8b4e33995dfbef1f87e357 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:00:13Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-a108a6b70f8b4e33995dfbef1f87e3572024-03-03T03:25:31ZengWileyHemaSphere2572-92412023-08-017e014785b10.1097/01.HS9.0000970580.01478.5b202308003-00819P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.Michael Gundesen0Fredrik Schjesvold1Annette Vangsted2Carsten Helleberg3Einar Haukås4Trine Silkjær5Elena Todorescu6Bo Amdi Jensen7Tobias S. Slørdahl8Jon Thor Asmussen9Hareth Nahi10Anders Waage11Niels Abildgaard12Thomas Lund131 Odense University Hospital, Department of Hematology2 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway3 Department of Hematology, Rigshospitalet, Copenhagen, Denmark3 Department of Hematology, Rigshospitalet, Copenhagen, Denmark4 Department of Blood and cancer diseases, Stavanger University Hospital, Norway5 Department of Hematology, Aarhus University Hospital, Denmark6 Department of Hematology Aalborg University Hospital, Denmark7 Department of Hematology, Zealand University Hospital, Denmark8 Department of Hematology, St. Olavs Hospital - Trondheim University Hospital9 Odense University Hospital, Department of radiology, Denmark10 Karolinska Institutet, Sweden8 Department of Hematology, St. Olavs Hospital - Trondheim University Hospital11 Department of Clinical Research, University of Southern Denmark, Denmark, Department of hematology12 Odense University Hospital, Department of Clinical Research, University of Southern Denmark, Denmarkhttp://journals.lww.com/10.1097/01.HS9.0000970580.01478.5b |
| spellingShingle | Michael Gundesen Fredrik Schjesvold Annette Vangsted Carsten Helleberg Einar Haukås Trine Silkjær Elena Todorescu Bo Amdi Jensen Tobias S. Slørdahl Jon Thor Asmussen Hareth Nahi Anders Waage Niels Abildgaard Thomas Lund P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW. HemaSphere |
| title | P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW. |
| title_full | P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW. |
| title_fullStr | P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW. |
| title_full_unstemmed | P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW. |
| title_short | P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW. |
| title_sort | p919 treatment of patients with multiple myeloma with zoledronic acid for four years instead of two years decreases risk of progressive bone disease without increasing risk of osteonecrosis of the jaw |
| url | http://journals.lww.com/10.1097/01.HS9.0000970580.01478.5b |
| work_keys_str_mv | AT michaelgundesen p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT fredrikschjesvold p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT annettevangsted p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT carstenhelleberg p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT einarhaukas p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT trinesilkjær p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT elenatodorescu p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT boamdijensen p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT tobiassslørdahl p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT jonthorasmussen p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT harethnahi p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT anderswaage p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT nielsabildgaard p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw AT thomaslund p919treatmentofpatientswithmultiplemyelomawithzoledronicacidforfouryearsinsteadoftwoyearsdecreasesriskofprogressivebonediseasewithoutincreasingriskofosteonecrosisofthejaw |